Glial progenitor-based repair of demyelinating neurological diseases - PubMed
Review
. 2007 Jan;18(1):93-104, x.
doi: 10.1016/j.nec.2006.10.009.
Affiliations
- PMID: 17244557
- DOI: 10.1016/j.nec.2006.10.009
Review
Glial progenitor-based repair of demyelinating neurological diseases
H Michael Keyoung et al. Neurosurg Clin N Am. 2007 Jan.
Abstract
Demyelinating diseases of the brain and spinal cord affect more than one-quarter million of Americans, with numbers reaching more than two million across the world. These patients experience not only the vascular, traumatic, and inflammatory demyelinations of adulthood but the congenital and childhood dysmyelinating syndromes of the pediatric leukodystrophies. Several disease-modifying strategies have been developed that slow disease progression, especially in the inflammatory demyelinations and in multiple sclerosis in particular. Yet, currently available disease modifiers typically influence the immune system and are neither intended to nor competent to reverse the structural neurologic damage attending acquired demyelination. Fortunately, however, the disorders of myelin lend themselves well to attempts at structural repair, because central oligodendrocytes are the primary, and often sole, victims of the underlying disease process. Given the relative availability and homogeneity of human oligodendrocyte progenitor cells, the disorders of myelin formation and maintenance may be especially compelling targets for cell-based neurologic therapy.
Similar articles
-
Stem cell-based strategies for treating pediatric disorders of myelin.
Goldman SA, Schanz S, Windrem MS. Goldman SA, et al. Hum Mol Genet. 2008 Apr 15;17(R1):R76-83. doi: 10.1093/hmg/ddn052. Hum Mol Genet. 2008. PMID: 18632701 Review.
-
Prospects of cell therapy for disorders of myelin.
Ben-Hur T, Goldman SA. Ben-Hur T, et al. Ann N Y Acad Sci. 2008 Oct;1142:218-49. doi: 10.1196/annals.1444.014. Ann N Y Acad Sci. 2008. PMID: 18990129 Review.
-
Mothe AJ, Tator CH. Mothe AJ, et al. Exp Neurol. 2008 Sep;213(1):176-90. doi: 10.1016/j.expneurol.2008.05.024. Epub 2008 Jun 10. Exp Neurol. 2008. PMID: 18586031
-
Munoz-Sanjuan I. Munoz-Sanjuan I. Expert Opin Ther Pat. 2009 Dec;19(12):1639-46. doi: 10.1517/13543770903443105. Expert Opin Ther Pat. 2009. PMID: 19939186 Review.
-
Progenitor cell-based treatment of glial disease.
Goldman SA. Goldman SA. Prog Brain Res. 2017;231:165-189. doi: 10.1016/bs.pbr.2017.02.010. Epub 2017 Apr 13. Prog Brain Res. 2017. PMID: 28554396 Free PMC article.
Cited by
-
Concise Review: Stem Cell-Based Treatment of Pelizaeus-Merzbacher Disease.
Osorio MJ, Rowitch DH, Tesar P, Wernig M, Windrem MS, Goldman SA. Osorio MJ, et al. Stem Cells. 2017 Feb;35(2):311-315. doi: 10.1002/stem.2530. Epub 2016 Nov 23. Stem Cells. 2017. PMID: 27882623 Free PMC article. Review.
-
Wang S, Bates J, Li X, Schanz S, Chandler-Militello D, Levine C, Maherali N, Studer L, Hochedlinger K, Windrem M, Goldman SA. Wang S, et al. Cell Stem Cell. 2013 Feb 7;12(2):252-64. doi: 10.1016/j.stem.2012.12.002. Cell Stem Cell. 2013. PMID: 23395447 Free PMC article.
-
Sim FJ, McClain CR, Schanz SJ, Protack TL, Windrem MS, Goldman SA. Sim FJ, et al. Nat Biotechnol. 2011 Sep 25;29(10):934-41. doi: 10.1038/nbt.1972. Nat Biotechnol. 2011. PMID: 21947029 Free PMC article.
-
Windrem MS, Schanz SJ, Guo M, Tian GF, Washco V, Stanwood N, Rasband M, Roy NS, Nedergaard M, Havton LA, Wang S, Goldman SA. Windrem MS, et al. Cell Stem Cell. 2008 Jun 5;2(6):553-65. doi: 10.1016/j.stem.2008.03.020. Cell Stem Cell. 2008. PMID: 18522848 Free PMC article.
-
Mesenchymal stem cells and induced pluripotent stem cells as therapies for multiple sclerosis.
Xiao J, Yang R, Biswas S, Qin X, Zhang M, Deng W. Xiao J, et al. Int J Mol Sci. 2015 Apr 24;16(5):9283-302. doi: 10.3390/ijms16059283. Int J Mol Sci. 2015. PMID: 25918935 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources